Treatments for are allergic fungal rhinosinusitis, bipolar I disorder, Hunter syndrome, Leber hereditary optic neuropathy, ovarian cancer, and schizophrenia under review.

Researchers from Carnegie Mellon University have discovered a way to target RNA that could lead to new treatment options for myotonic dystrophy type 1 (DM1), the most common adult-onset form of ...

CNS-active drugs are associated with an increased risk of falls, delirium, and hospitalization. They are often prescribed for ...

A new LUMC study has changed our understanding of how cells work. Researchers have discovered that the CFAP20 protein acts as ...

Much of pancreatic cancer’s evasive and deadly nature may come down to low levels of one gene. In A Nutshell Early detection, ...

Venetia Zachariou, PhD, Edward Avedisian Professor and chair of pharmacology, physiology & biophysics at Boston University Chobanian & Avedisian School of Medicine, has been named a Class of 2025 ...

New research has identified that neuroinflammation driven by microglia (immune cells in the brain) is a primary underlying ...

Deep inside the brain, every thought and memory begins with a burst of electrical activity. For years, scientists have tried ...

Scientists have found that adding a missing phospholipid back into the bloodstream might help improve blood flow and reduce ...

Dr. Wagle says that artificial fats can get incorporated into brain cell membranes, changing their structure and making it ...

Researchers have identified a brain protein whose absence leads to memory loss and Alzheimer’s-like damage in mice.

Enthorin Therapeutics, LLC, a biotechnology company focused on circuit-modulating treatments for neurological and neurodevelopmental disorders, announced that its licensing partner for MRM-3379 ...